Company: ANTX
Filing Date: 2025-03-25
Form Type: 10-K
Source: 0000950170-25-044366
Chunk: 161

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-03-25
Form: 10-K
Item: Item 1B
Chunk 161
---
 —

    8,338

    —

    —

    8,338

    Unrealized loss on available-for-sale investments

    —

    —

    —

    (244
    )

    —

    (244
    )

    Net loss

    —

    —

    —

    —

    (51,321
    )

    (51,321
    )

    Balances at December 31, 2024

    29,919,634

    $
    —

    $
    287,594

    $
    31

    $
    (205,776
    )
     
    $
    81,849

The accompanying notes are an integral part of these financial statements.

F-5

AN2 THERAPEUTICS, INC.

STATEMENTS OF CASH FLOWS

(in thousands)

    Year EndedDecember 31,

    2024

    2023

    Cash flows from operating activities

    Net loss
     
    $
    (51,321
    )
     
    $
    (64,732
    )

    Adjustments to reconcile net loss to net cash used in operating activities:

    Stock-based compensation expense

    8,338

    8,412

    Non-cash operating lease expense

    —

    53

    Net accretion of discount on investments

    (3,279
    )

    (2,855
    )

    Changes in operating assets and liabilities:

    Prepaid expenses and other assets

    807

    (1,026
    )

    Accounts payable

    641

    553

    Accrued compensation

    (2,342
    )

    1,850

    Accrued liabilities

    (2,227
    )

    3,844

    Operating lease liabilities

    —

    (53
    )

    Other current liabilities

    126

    666

    Net cash used in operating activities

    (49,257
    )

    (53,288
    )

    Cash flows from investing activities

    Purchases of investments

    (46,751
    )

    (132,178
    )

    Maturities of investments

    101,340

    88,900

    Net cash provided by (used in) investing activities

    54,589

    (43,278
    )

    Cash flows from financing activities

    Proceeds from issuance